A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Chen, Der Yuan ^a,b,c,d   Yao, Ling ^b   Chen, Yi Ming ^a,b   Lin, Chi Chen ^c   Huang, Kui Chou ^b   Chen, Szu Ting ^a   Lan, Joung Liang ^a,b,e,f   Hsieh, Shie Liang Edmond ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MEMBRANE PROTEIN; PROTEIN MDL 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DAP12 GENE; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE; GENE ACTIVATION; GENE FREQUENCY; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; KNEE OSTEOARTHRITIS; MALE; MDL 1 GENE; MONOCYTE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATION MEDIATORS; JOINTS; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SYNOVIAL MEMBRANE;

EID: 84907828314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086105     Document Type: Article

References (41)

1. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916. (Pubitemid 32224400)
2. Goldring SR, Gravallese EM (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12: 195-199. (Pubitemid 30238387)
3. Koga T, Inui M, Inoue K, Kim S, Suematsu A, et al. (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758-763. (Pubitemid 38508286)
4. Mócsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, et al. (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A. 101: 6158-6163. (Pubitemid 38520544)
5. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
6. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7: 429-442. (Pubitemid 46834849)
7. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW (2002) Interleukin 17 synergies with tumor necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis. 61: 870-876.
8. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res Ther. 3: 168-177. (Pubitemid 32303433)
9. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, et al. (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 63: 1062-1068. (Pubitemid 39120355)
10. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, et al. (2012) Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 71: 198-205.
11. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, et al. (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54 1063-1074. (Pubitemid 43672919)
12. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot HJ, et al. (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology 50: 196-203.
13. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM et al. (2010) A humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase 1 randomized double-blind, placebo-controlled, proof of concept study. Arthritis Rheum 62: 929-939.
14. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R (2006) PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 116: 2869-2879. (Pubitemid 44684472)
15. Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83: 170-179.
16. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, et al. (1997) Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol. 158: 5083-5086. (Pubitemid 127681207)
17. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH (1998) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391: 703-707. (Pubitemid 28113218)
18. Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, et al. (2004) The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res 19: 224-234. (Pubitemid 38116736)
19. Crotti TN, Dharmapatni AA, Alias E, Zannettino ACW, Smith MD, et al. (2012) The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid joints. Arthritis Res Ther 14: R245.
20. Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL (1999) Myeloid DAP12-associated lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA. 96: 9792-9796. (Pubitemid 29398811)
21. Aoki N, Kimura Y, Kimura S, Nagato T, Azumi M, et al. (2009) Expression and functional role of MDL-1 (CLEC5A) in mouse myeloid lineage cells. J Leukoc Biol. 85: 508-517.
22. Joyce-Shaikh B, Bigler ME, Chao CC, Murphy EE, Blumenschein WM, et al. (2010) Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med. 207: 579-589.
23. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, et al. (2008) Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453: 672-678.
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) The 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-8.
25. Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, et al. (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis May 28.
26. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44-48.
27. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al. (2011) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 70: 631-637.
28. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, et al. (1998) Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 41: 1583-1590. (Pubitemid 28459916)
29. Altman R, Asch E, Bloch D, Bole G, Borenstein D, et al. (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29: 1039-1049.
30. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162: 156-159. (Pubitemid 17064313)
31. Gibson UEM, Heid CA, Williams PM (1996) A novel method for real time quantitative PCR. Genome Res. 6: 995-1001. (Pubitemid 26388092)
32. Gingras MC, Lapillonne H, Margolin JF (2001) TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol. 38: 817-824. (Pubitemid 34260883)
33. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 25: 402-408. (Pubitemid 34164012)
34. Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, et al. (2013) Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. Arthritis Res Ther 15: R39.
35. Yang XM, Jiang LF, Tang YX, Yin Y, Liu WQ, et al. (2010) Establishment and characterization of dengue virus type 2 nonstructural protein 1 specific T cell lines. Comp Immunol Microbiol Infect Dis 33: e75-80.
36. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL, et al. (2000) DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 192: 1059-1067.
37. Tomasello E, Cant C, Buhring HJ, Vely F, Andre P, et al. (2000) Association of signal-regulatory proteins beta with KARAP/DAP-12. Eur J Immunol 30: 2147-2156. (Pubitemid 30655753)
38. Inui M, Kikuchi Y, Aoki N, Endo S, Maeda T, et al. (1999) Signal adaptor DAP10 associates with MDL-1 and triggers osteoclastogenesis in cooperation with DAP12. Proc Natl Acad Sci USA. 106: 4816-4821.
39. Wu J, Song Y, Bakker AB, Bauer S, Spies T, et al. (1999) An activating receptor complex on natural killer and T cells formed by NKG2D and DAP10. Science 285: 730-732.
40. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, et al. (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 363: 1303-1312.
41. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, et al. (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63: 337-345.